{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
          "line_ref": "L31"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination increases the breadth of the peptide repertoire appearing on MHC-I.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
          "line_ref": "L29"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "Intratumoral mRNA vaccine sensitizes tumors to anti-PD-L1 therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses",
          "line_ref": "L56"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C04",
      "claim": "SARS-CoV-2 mRNA vaccination status is associated with improved survival in human patients receiving ICI.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation."
    }
  ]
}